Unit of Immuno-Biotherapy of Melanoma and Solid Tumors, Division of Experimental Oncology, IRCSS San Raffaele Scientific Institute, Milan, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, and Istituto Oncologico Veneto IRCCS, Padova, Italy.
Cytokine Growth Factor Rev. 2017 Aug;36:1-3. doi: 10.1016/j.cytogfr.2017.06.004. Epub 2017 Jun 16.
The explosion in the immuno-oncology field, exemplified by the clinical implementation of immune checkpoint inhibitor blockade and other immunotherapeutic strategies was quickly recognized by the Italian biomedical community, thanks to the networking activities of the Italian Network for Tumor Biotherapy (NIBIT), which has been active since 2004 in the diffusion of new scientific and clinical findings in the fields of tumor immunology and immunotherapy. Numerous activities of NIBIT have also helped to overcome the hurdles associated with the clinical implementation of cancer immune-biotherapeutic strategies at the national and international levels. Looking forward, a concerted interaction of NIBIT with existing European networks focused on cancer bio-immunotherapy will further contribute to the development of improved therapies in the immuno-oncology field. This Introduction briefly summarizes the history and objectives of NIBIT, as well as the current activities of the Network.
免疫肿瘤学领域的爆炸式发展，以免疫检查点抑制剂阻断和其他免疫治疗策略的临床实施为例，很快就被意大利生物医学界所认识，这要归功于意大利肿瘤生物治疗网络（NIBIT）的网络活动，该网络自 2004 年以来一直致力于传播肿瘤免疫学和免疫治疗领域的新科学和临床发现。NIBIT 的众多活动还帮助克服了在国家和国际层面实施癌症免疫生物治疗策略所面临的障碍。展望未来，NIBIT 与专注于癌症生物免疫治疗的现有欧洲网络的协同互动将进一步促进免疫肿瘤学领域改进治疗方法的发展。这篇引言简要总结了 NIBIT 的历史和目标，以及该网络目前的活动。
